+471.3%
CIFR vs MRNA
+27.9%
+443.4%
-71.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.7% | +0.7% | -6.4% | -5.7% |
| 7D | -8.2% | -8.2% | 0.0% | -7.6% |
| 30D | -7.4% | +125.6% | -132.9% | -22.8% |
| 3M | -24.2% | +197.1% | -221.2% | -44.1% |
| 6M | +14.2% | +148.5% | -134.3% | -10.6% |
| YTD | +8.0% | +363.3% | -355.3% | -33.8% |
| 1Y | +55.5% | +462.0% | -406.5% | -13.1% |
| All | +471.3% | +27.9% | +443.4% | +372.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling